Impact of CYP2D6 genotype on postoperative tramadol analgesia.
about
Opioid therapy pharmacogenomics for noncancer pain: efficacy, adverse events, and costsProgress in genetic studies of pain and analgesiaApplications of CYP450 testing in the clinical settingTramadol Extended-Release for the Management of Pain due to OsteoarthritisTolerance and withdrawal from prolonged opioid use in critically ill children.Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol.Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affectCYP2D6 in the metabolism of opioids for mild to moderate pain.Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotypePharmacogenomic considerations in opioid analgesia.Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.Recent advances in the use of opioids for cancer painPharmacogenomic considerations in the opioid management of painEscitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain.Genetics and genomics in nursing: evaluating Essentials implementationThe cytochrome P450 2D6*10 genetic polymorphism alters postoperative analgesia.Genetics and variability in opioid response.Pharmacogenetics of analgesic drugsPharmacogenetics and anesthesiologists.Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.Role of cytochrome P450 genotype in the steps toward personalized drug therapy.Pharmacogenetics: Using Genetic Information to Guide Drug Therapy.Pharmacogenetics of opioids.The pharmacogenetics of analgesia.Basic pharmacology relevant to drug abuse assessment: tramadol as example.Pharmacogenetics of analgesics: toward the individualization of prescription.Current evidence for a modulation of low back pain by human genetic variants.Tramadol metabolism to O-desmethyl tramadol (M1) and N-desmethyl tramadol (M2) by dog liver microsomes: Species comparison and identification of responsible canine cytochrome P-450s (CYPs).Personalized therapy in pain management: where do we stand?Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance.From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics.Pain management in patients with cancer: focus on opioid analgesics.Pain, analgesia and genetics.Pharmacogenetics of pain and analgesia.Opioid genetics: the key to personalized pain control?Pharmacogenomics of opioids and perioperative pain management.Personalized treatment of pain.Association Between Human Pain-Related Genotypes and Variability in Opioid Analgesia: An Updated Review.Analgesic prescribing in palliative care.The Pharmacogenetics of Tramadol.
P2860
Q21284753-284898AC-D0C4-435A-9793-D52144861C8BQ24289028-FB89E71A-CD15-41E2-AD68-755F64DD249CQ24621760-69F47591-69A0-4E28-B475-E52E38277562Q27015822-D661CAB8-BA8B-4F75-BA07-5BBCFFBD55D3Q30428413-92071EAB-C632-4650-864E-DF4F69A15AB4Q33351201-E1B3A4DA-BFB0-4D0A-8520-B5AA1E4B6AACQ33838839-87F97570-0BB2-4407-BBCF-797E14B1E79BQ34178485-BB1CA817-F929-4368-84B7-4F3E3DFDA0B6Q34243414-630717CE-EEB9-42B3-A472-3B7E1CA1FB2CQ34316700-11D0B349-7C3F-42C6-8C8A-88CDA7FACB78Q34399802-41B3034B-155B-440B-8078-F855F5823B9EQ34418203-91B970F3-F68D-444A-B28E-F9588480456BQ34971560-FB2BB556-7895-4590-A96E-9ADAE8F28CAFQ34999764-AEFCC4D6-65A0-492F-8FEB-4EE271C45FB1Q35050883-D3A62E59-2DD8-42AC-8513-91C3B0DFAACAQ35481239-0BF66CC1-C59A-41D4-892B-E00114FCF7CBQ36057709-B964811C-457B-43CE-9523-8535F765471EQ36110592-AD481A6F-F1F6-41B1-9FDA-653F136E1CEEQ36317007-E7302840-E4BD-44EB-BABA-C7985AB92FD7Q36390262-611B161D-22C7-4B14-8B52-B66D8DB3A6A6Q36441521-FD15F85A-972D-46FE-9F5C-CE71D23077CDQ36508972-1795D1AE-D6B2-44A8-8F58-56AD52056BAAQ36752672-1C3DC3F9-4625-4477-93CB-AB979F8260BAQ36967259-90821CD5-3C1B-49D9-B662-A9BD73C3D1BCQ37100302-4D4C3080-B124-47CA-B956-0367DE425E9CQ37205954-4ECB6D2F-8C48-4653-BBBA-117F5C7BE1B6Q37396519-A57A5FEE-2788-4AB8-ABC2-B81168907525Q37427891-F9C56009-9DC5-452D-9A0E-A758E1769706Q37760955-E9B973FB-A571-4455-A9CE-363B9B346FE8Q37781110-F5D7A8A1-F6DE-4741-8D3C-1F31B44C930EQ37806982-EFC2B44D-CE4E-4F97-85D3-6BC5A6C59F9DQ37863588-5753A3A0-9FC4-4842-B348-37E4F9432B87Q37944353-E4463D7D-3659-4E39-BF2B-DFA1B5A4058FQ38025139-3DE353C9-4284-416C-8DB1-B907CE792717Q38025200-80FA5EA5-75AB-4114-9631-0EB348F0B080Q38061498-7D1146A8-F075-4BF9-B83E-075EB84BDCA4Q38071975-7A345FE8-B6AC-47EF-AF96-7B3B24AB9886Q38247246-9F916F4C-EAFE-4C0F-9D3C-2ACFD02C547EQ38285562-1ED356AE-7B6C-4E76-A154-3AC8CC3F3E00Q38441114-8DFE53C1-1D25-41A6-AA40-1B4F6DB1EAE7
P2860
Impact of CYP2D6 genotype on postoperative tramadol analgesia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Impact of CYP2D6 genotype on postoperative tramadol analgesia.
@en
Impact of CYP2D6 genotype on postoperative tramadol analgesia.
@nl
type
label
Impact of CYP2D6 genotype on postoperative tramadol analgesia.
@en
Impact of CYP2D6 genotype on postoperative tramadol analgesia.
@nl
prefLabel
Impact of CYP2D6 genotype on postoperative tramadol analgesia.
@en
Impact of CYP2D6 genotype on postoperative tramadol analgesia.
@nl
P2093
P1433
P1476
Impact of CYP2D6 genotype on postoperative tramadol analgesia.
@en
P2093
Andreas Hoeft
Bettina Bayerer
Fabienne Höthker
Frank Stuber
Katja Lehnen
Stephanie Wolf
Ulrike M Stamer
P304
P356
10.1016/S0304-3959(03)00212-4
P407
P577
2003-09-01T00:00:00Z